SCHEMBL3056191

SCHEMBL3056191

CC(C)Cc1ccc2c(c1)C(CNNC(=O)O)c1ccccc1-2

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.38
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28972124 0.82 KMT2A (0.43)
SCHEMBL1694504 0.79 PTGS1 (0.39)
SCHEMBL3057349 0.74 MAPT (0.39) PTPN1
SCHEMBL2936143 0.70 GABRA1 (0.44) PPARG
SCHEMBL88302 0.67 HTR2A (0.45)
SCHEMBL29579635 0.67 HTR2A (0.45)
SCHEMBL28856363 0.67 GABRA1 (0.41)
SCHEMBL18516821 0.66 PTPN1 (0.41) PTPN1
Ammonia Solution, Strong SCHEMBL28099493 0.65 HTR2A (0.44)
SCHEMBL8084158 0.65 AKR1B1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708370-B2 Azapeptides as CD36 binding compounds VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2017-07-18 US disclosed
EP-2160404-B1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS VALORISATION RECHERCHE LTD PARTNERSHIP (CA) 2016-08-24 EP disclosed
US-20150329591-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE (CA) 2015-11-19 US disclosed
US-9115171-B2 Azapeptides as CD36 binding compounds VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2015-08-25 US disclosed
US-20130203686-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS INSERM (FR) 2013-08-08 US disclosed
US-8435954-B2 Azapeptides as CD36 binding compounds VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2013-05-07 US disclosed
US-20100210566-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2010-08-19 US disclosed
EP-2160404-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS UNIVERSITE DE MONTREAL (CA) 2010-03-10 EP disclosed
WO-2008154738-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS UNIVERSITE DE MONTREAL (CA) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329591-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS MSR1, ASGR1, LDLR PTPN1 1050/4885PPARG 353/4885PPARA 175/4885
US-20130203686-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS MSR1, ASGR1, SCARB1 PTPN1 931/4885PPARG 433/4885PPARA 242/4885
US-20100210566-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS GHRHR, GHSR, GNRHR PTPN1 695/4885PPARG 301/4885PPARA 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.